publication venue for
- Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. 34:2163-2172. 2017
- Potential Impact of Biologically Derived Hyaluronic Acid on Quality of Life in Patients with Knee Osteoarthritis in the United States. 33:2200-2210. 2016
- Response to: Important Considerations When Determining the Cost-effectiveness of Viscosupplements in the Treatment of Knee Osteoarthritis. 33:2273-2276. 2016
- Promoting Patient and Family Partnerships in Ambulatory Care Improvement: A Narrative Review and Focus Group Findings. 33:1417-1439. 2016
- Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee. 33:998-1011. 2016
- A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope®) During a Phase III Clinical Trial. 32:148-156. 2015
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. 31:1008-1009. 2014
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. 30:870-884. 2013
- Obesity and Mental Illness: Implications for Cognitive Functioning. 30:577-588. 2013
- Blood pressure control rates with an antihypertensive regimen including trandolapril in a canadian usual-care setting. 28:789-798. 2011
- Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. 27:796-813. 2010
- Erratum to: New pharmacotherapy for stroke prevention in atrial fibrillation. 27:493-493. 2010
- New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. 26:1058-1071. 2009
- Ramelteon: a review of its therapeutic potential in sleep disorders. 26:613-626. 2009
- The dilution of benzalkonium chloride (BAK) in the tear Film. 23:835-841. 2006
- Twice-daily and once-daily nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. 19:9-16. 2002
- Nedocromil sodium in golfers with seasonal allergic conjunctivitis. 18:195-204. 2001
- Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. 17:140-147. 2000